Professor Gerald Holtmann
Professor

Gerald Holtmann

Email: 

Background

Prof Holtmann is a Clinical Academic in the field of Gastroenterology & Hepatology and Director of Clinical Innovation. He is also Director of the Department of Gastroenterology & Hepatology at the Princess Alexandra Hospital in Queensland and serves on the Board of Directors of the West Moreton Hospital and Health Service and UQ Healthcare. He is a Fellow of Royal Australian Collge of Physicians (RACP, Sydney), the Royal College of Physicians (RCP, London) and Fellow of the Australian Academy of Health and Medical Sciences (AAHMS, Canberra). Besides his Medical Qualifications he also obtained a Master of Business Administration. After completing the clinical training in Medicine and Gastroenterology at the University of Essen in Germany and the Mayo Clinic in Rochester, Minnesota in the United States, he has gained substantial leadership and managerial experience within the health care setting as Director of large Gastroenterology Departments, CEO and General Manager of a University Hospital and Health Care Facilities and has served on the Board of the University Hospital Essen in Germany. His research is in the field of Neurogastroenterology has resulted in peer reviewed publications in key journal including the NEJM, Lancet, Gastroenterology and Gut. More recently his rersearch focus is on the role of the gut microbiome, mucosal and systemic inflammation and brain-gut interactions.

Availability

Professor Gerald Holtmann is:
Available for supervision
Media expert

Search Professor Gerald Holtmann’s works on UQ eSpace

669 works between 1937 and 2026
All (669) Journal Article (455) Conference Publication (210) Book Chapter (4)

1 - 20 of 669 works

2026

Journal Article

Meta‐Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders

Kulin, Dmitrii, Holtmann, Gerald, Fairlie, Thomas, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Drossman, Douglas A., Jones, Michael P., Aziz, Qasim and Shah, Ayesha (2026). Meta‐Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders. Alimentary Pharmacology & Therapeutics, 64 (5) apt.70856, 574-589. doi: 10.1111/apt.70856

Meta‐Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders

2026

Journal Article

Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial

Khoo, Emi, Holtmann, Gerald and Begun, Jakob (2026). Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial. BMJ Open, 16 (7) e118940, e118940-7. doi: 10.1136/bmjopen-2026-118940

Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial

2026

Journal Article

The challenges of performing controlled trials of diet therapies in gastroenterology

Day, Alice S., Yao, Chu K., Ford, Alexander C., Holtmann, Gerald and Halmos, Emma P. (2026). The challenges of performing controlled trials of diet therapies in gastroenterology. JGH Open, 10 (7) e70439. doi: 10.1002/jgh3.70439

The challenges of performing controlled trials of diet therapies in gastroenterology

2026

Journal Article

Hospital-admitted injection-related infections among incarcerated people who inject drugs in Australia: a retrospective cohort study

Palmer, Andrew, Carter, Matthew, Yeo, Jeremy, Shim, Cecilia, Connor, Jason, Hayllar, Jeremy, Holtmann, Gerald, Moy, Naomi, Playford, Elliott G., Runnegar, Naomi and Clark, Paul J. (2026). Hospital-admitted injection-related infections among incarcerated people who inject drugs in Australia: a retrospective cohort study. Medical Journal of Australia, 224 (6). doi: 10.5694/mja2.70224

Hospital-admitted injection-related infections among incarcerated people who inject drugs in Australia: a retrospective cohort study

2026

Journal Article

Role of anxiety and depression on the interplay between disorders of gut-brain interaction and eating disorders

Egboh, SC, Koloski, NA, Jones, MP, Shah, A, Holtmann, G and Talley, NJ (2026). ROLE OF ANXIETY AND DEPRESSION ON THE INTERPLAY BETWEEN DISORDERS OF GUT-BRAIN INTERACTION AND EATING DISORDERS. Clinical and Translational Gastroenterology, Publish Ahead of Print 10.14309/ctg.0000000000001025. doi: 10.14309/ctg.0000000000001025

Role of anxiety and depression on the interplay between disorders of gut-brain interaction and eating disorders

2026

Journal Article

Impact of bariatric surgery on alcohol‐use disorder and alcohol‐related liver disease: a retrospective study

Williams, Thomas J., Palmer, Andrew J., Connor, Jason P., Holtmann, Gerald and Clark, Paul J. (2026). Impact of bariatric surgery on alcohol‐use disorder and alcohol‐related liver disease: a retrospective study. Addiction add.70487. doi: 10.1111/add.70487

Impact of bariatric surgery on alcohol‐use disorder and alcohol‐related liver disease: a retrospective study

2026

Conference Publication

IDDF2026-ABS-0193 Development and validation of GI symptoms animated pictograms (GAPs) as a diagnostic tool for gi dysfunction among patients with cognitive impairment

Ehab Samir Ayad, Mina, Yeh Lee, Yeong, Holtmann, Gerald, Kuo, Braden, Schmulson, Max, Viet Hang, Dao, Ghoshal, Uday, Marie Lawenko, Rona, Miftahussurur, Muhammad, Ali, Enaam, Faizal, Mohd, Kueh, Erica and Oshima, Tadayuki (2026). IDDF2026-ABS-0193 Development and validation of GI symptoms animated pictograms (GAPs) as a diagnostic tool for gi dysfunction among patients with cognitive impairment. BMJ Publishing Group Ltd and British Society of Gastroenterology. doi: 10.1136/gutjnl-2026-iddf.271

IDDF2026-ABS-0193 Development and validation of GI symptoms animated pictograms (GAPs) as a diagnostic tool for gi dysfunction among patients with cognitive impairment

2026

Journal Article

A clinical practice update for the management of patients with disorders of gut-brain interaction and altered food intake behavior

Shah, Ayesha, Talley, Nicholas J., Knowles, Simon R., Duncanson, Kerith, Koloski, Natasha, Connor, Jason P., Day, Andrew S., Almehdawy, Basil, Basnayake, Chamara, Burgell, Rebecca, Carey, Sharon, Cock, Charles, Daker, Charlotte, Kaushik, Vishal, Kent, Dan, Kellar, Trina, Lane, Katherine, Martin, Neal, Malcolm, Allison, Murphy, Kate Elizabeth, Sharp, Gemma, Tuck, Caroline, Jones, Michael, Thapar, Nikhil and Holtmann, Gerald (2026). A clinical practice update for the management of patients with disorders of gut-brain interaction and altered food intake behavior. Neurogastroenterology and Motility, 38 (5) e70337. doi: 10.1111/nmo.70337

A clinical practice update for the management of patients with disorders of gut-brain interaction and altered food intake behavior

2026

Conference Publication

Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION

Fairlie, Thomas, Celine, Patricia, Shah, Ayesha, Lim, Yenkai, Morrison, Mark and Holtmann, Gerald (2026). Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION. Elsevier BV. doi: 10.1016/s0016-5085(26)05814-2

Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION

2026

Journal Article

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( <scp>SIBO</scp> )

Shah, Ayesha, Holtmann, Gerald and Gibson, Peter R. (2026). Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( SIBO ). JGH Open, 10 (5) e70419. doi: 10.1002/jgh3.70419

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( <scp>SIBO</scp> )

2026

Journal Article

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

Wilmes, Sophie, Holtmann, Gerald, Shah, Ayesha and Moy, Naomi (2026). Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW. Gastrointestinal Endoscopy, 103 (5), S-2343. doi: 10.1016/s0016-5107(26)05474-x

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

2026

Conference Publication

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

Wilmes, Sophie, Holtmann, Gerald, Shah, Ayesha and Moy, Naomi (2026). Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW. Elsevier BV. doi: 10.1016/s0016-5085(26)05543-5

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

2026

Journal Article

Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS

Gonsalves, Nirmala, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Ravikumar, Pranali, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS. Gastrointestinal Endoscopy, 103 (5), S-817. doi: 10.1016/s0016-5107(26)02133-4

Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS

2026

Conference Publication

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

Ma, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL. Elsevier BV. doi: 10.1016/s0016-5085(26)01797-x

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

2026

Conference Publication

Advancing hepatitis C elimination in prisons: a state-specific modelling study of integrated harm-reduction and addiction interventions

Palmer, Andrew, Anandan, Aathavan Shanmuga, Carter, Matthew, Fraz, Ezaam, Clark, Paul, Connor, Jason, Holtmann, Gerald, Runnegar, Naomi, Playford, Geoffrey, Hayllar, Jeremy, Scott, Nick and Houdroge, Farah (2026). Advancing hepatitis C elimination in prisons: a state-specific modelling study of integrated harm-reduction and addiction interventions. EASL Congress 2026, Barcelona, Spain, 27-30 May 2026. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0168-8278(26)02182-3

Advancing hepatitis C elimination in prisons: a state-specific modelling study of integrated harm-reduction and addiction interventions

2026

Conference Publication

Prevalence of orthostatic intolerance in patients with disorders of gut-brain interaction: a systematic review and meta-analysis

Ayaki, Kana, Shah, Ayesha, Fairlie, Thomas, Kulin, Dmitrii, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Aziz, Qasim, Drossman, Douglas A., Jones, Michael P. and Holtmann, Gerald (2026). Prevalence of orthostatic intolerance in patients with disorders of gut-brain interaction: a systematic review and meta-analysis. Digestive Disease Week (DDW) 2026, Chicago, IL, United States, 2-5 May 2026. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(26)04699-8

Prevalence of orthostatic intolerance in patients with disorders of gut-brain interaction: a systematic review and meta-analysis

2026

Conference Publication

582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

Shah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). 582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI. Elsevier BV. doi: 10.1016/s0016-5085(26)05702-1

582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

2026

Journal Article

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

Ma, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL. Gastrointestinal Endoscopy, 103 (5), S-627. doi: 10.1016/s0016-5107(26)01728-1

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

2026

Conference Publication

COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

Shah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI. Digestive Disease Week (DDW), Chicago Il, May 02-05, 2026. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.

COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

2026

Conference Publication

A comparison of diagnostic methodologies for small intestinal bacterial overgrowth: aspirate culture, breath testing and the Atmo capsule

Shah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). A comparison of diagnostic methodologies for small intestinal bacterial overgrowth: aspirate culture, breath testing and the Atmo capsule. Digestive Disease Week (DDW) 2026, Chicago, IL, United States, 2-5 May 2026. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(26)05815-4

A comparison of diagnostic methodologies for small intestinal bacterial overgrowth: aspirate culture, breath testing and the Atmo capsule

Past funding

  • 2022 - 2026
    ARC Training Centre for Behavioural Insights for Technology Adoption (BITA) (ARC Industrial Transformation Training Centre Administered by QUT)
    Queensland University of Technology
    Open grant
  • 2021 - 2025
    A practice change for patients with severe chronic, clinically unexplained gastrointestinal symptoms: A randomised, controlled intervention to assess efficacy and cost-effectiveness
    NHMRC IDEAS Grants
    Open grant
  • 2020 - 2024
    Modulation of the Gastrointestinal Microbiome with probiotics and subsequent Methane production as a novel approach to treat constipation: A Proof of Principle Study (TRI Sport Grant led by PAH)
    Metro South Hospital and Health Service
    Open grant
  • 2020 - 2025
    Targeting the gut microbiome as a treatment for Primary Sclerosing Cholangitis: The Queensland Clinical Network Study
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2019 - 2024
    Centre for Research Excellence in Digestive Health (NHMRC CRE administered by University of Newcastle)
    University of Newcastle
    Open grant
  • 2016
    Establishing a gnotobiotic germ-free mouse facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016
    The Australian human microbiota project-microbe isolation facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2015 - 2018
    Pathophysiology of functional dyspepsia: Integration of upper gut function, inflammation and a systems biology approach.
    NHMRC Project Grant
    Open grant
  • 2014 - 2017
    Functional dyspepsia: Characterisation of the immunopathology and testing a novel therapeutic strategy (NHMRC Project Grant administered by the University of Newcastle)
    University of Newcastle
    Open grant

Availability

Professor Gerald Holtmann is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    IBD and mental health tools: a holistic approach to discovery and appropriate tool.

    Principal Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    Gastrointestinal symptoms and Disorders of Gut-Brain Interaction: clinical manifestations and treatment response

    Principal Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    Targeting the gastrointestinal mucosa associated microbiome to improve clinical outcomes

    Associate Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    Study of TOfacitinib for the treatment of chronic Pouchitis

    Associate Advisor

    Other advisors: Associate Professor Jakob Begun

  • Doctor Philosophy

    The role of the gut microbiome in alcohol related liver disease

    Associate Advisor

    Other advisors: Professor Jason Connor, Honorary Professor Paul Clark

Completed supervision

Enquiries

Contact Professor Gerald Holtmann directly for media enquiries about:

  • colon cancer screening
  • Gastroenterology
  • Gut Health
  • Microbiome
  • Neurogastroenterology

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au